Year 2024,
, 61 - 63, 29.04.2024
Elif Işıklar
,
Berivan Akdoğan
Uygar Yavaş
İsmail Demir
References
- Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, Beyer G, Sutton R. Acute Pancreatitis: Diagnosis and Treatment. Drugs. 2022 Aug;82(12):1251-1276. doi: 10.1007/s40265-022-01766-4.
- Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf. 2008;31(10):823-37. doi: 10.2165/00002018-200831100-00002.
- Simons-Linares CR, Elkhouly MA, Salazar MJ. Drug-Induced Acute Pancreatitis in Adults: An Update. Pancreas. 2019 Nov/Dec;48(10):1263-1273. doi: 10.1097/MPA.0000000000001428.
- Juanatey A, Blanco-Garcia L, Tellez N. Ocrelizumab: its efficacy and safety in multiple sclerosis. Rev Neurol. 2018 Jun 16;66(12):423-433.
- Spanier BW, Tuynman HA, van der Hulst RW, Dijkgraaf MG, Bruno MJ. Acute pancreatitis and concomitant use of pancreatitis-associated drugs. Am J Gastroenterol. 2011 Dec;106(12):2183-8. doi: 10.1038/ajg.2011.303.
- Sadr-Azodi O, Mattsson F, Bexlius TS, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Intern Med. 2013 Mar 25;173(6):444-9. doi: 10.1001/jamainternmed.2013.2737.
- Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007 Jun;5(6):648-61; quiz 644. doi: 10.1016/j.cgh.2006.11.023.
- Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol. 2000 May;12(5):597-605. doi: 10.1093/intimm/12.5.597.
A case of recurrent acute pancreatitis following ocrelizumab use
Year 2024,
, 61 - 63, 29.04.2024
Elif Işıklar
,
Berivan Akdoğan
Uygar Yavaş
İsmail Demir
Abstract
Acute pancreatitis is an acute inflammatory process of the pancreas. Drugs are a relatively rare cause of acute pancreatitis with an incidence of 0.1-2%. Ocrelizumab is a monoclonal antibody that causes peripheral B lymphocyte suppression by targeting CD20 receptors on B lymphocytes. In this case report, we aimed to present a case of acute pancreatitis after ocrelizumab use. It is thought that suppression of B lymphocytes by ocrelizumab may induce proinflammatory cytokine release and may also cause pancreatitis by disrupting T lymphocyte regulation. Therefore, ocrelizumab should be considered in the etiology of pancreatitis in patients receiving ocrelizumab treatment.
References
- Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, Beyer G, Sutton R. Acute Pancreatitis: Diagnosis and Treatment. Drugs. 2022 Aug;82(12):1251-1276. doi: 10.1007/s40265-022-01766-4.
- Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf. 2008;31(10):823-37. doi: 10.2165/00002018-200831100-00002.
- Simons-Linares CR, Elkhouly MA, Salazar MJ. Drug-Induced Acute Pancreatitis in Adults: An Update. Pancreas. 2019 Nov/Dec;48(10):1263-1273. doi: 10.1097/MPA.0000000000001428.
- Juanatey A, Blanco-Garcia L, Tellez N. Ocrelizumab: its efficacy and safety in multiple sclerosis. Rev Neurol. 2018 Jun 16;66(12):423-433.
- Spanier BW, Tuynman HA, van der Hulst RW, Dijkgraaf MG, Bruno MJ. Acute pancreatitis and concomitant use of pancreatitis-associated drugs. Am J Gastroenterol. 2011 Dec;106(12):2183-8. doi: 10.1038/ajg.2011.303.
- Sadr-Azodi O, Mattsson F, Bexlius TS, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Intern Med. 2013 Mar 25;173(6):444-9. doi: 10.1001/jamainternmed.2013.2737.
- Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007 Jun;5(6):648-61; quiz 644. doi: 10.1016/j.cgh.2006.11.023.
- Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol. 2000 May;12(5):597-605. doi: 10.1093/intimm/12.5.597.